ULTIo — Ultimovacs ASA Income Statement
0.000.00%
Last trade - 00:00
- NOK61.52m
- -NOK107.92m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 66.2 | 124 | 164 | 184 | 216 |
Operating Profit | -66.2 | -124 | -164 | -184 | -216 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -61.2 | -121 | -165 | -168 | -189 |
Provision for Income Taxes | |||||
Net Income After Taxes | -61.2 | -121 | -165 | -168 | -189 |
Net Income Before Extraordinary Items | |||||
Net Income | -61.2 | -121 | -165 | -168 | -189 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -61.2 | -121 | -165 | -168 | -189 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.67 | -3.98 | -5.09 | -4.9 | -5.5 |
Dividends per Share |